Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue?

References

• Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. Second Edition. Philadelphia (PA):Lippincott, Williams and Wilkins; 1999. Page 430
   Google Scholar
• Danan G, Bénichou C. Causality assessment of adverse reactions to drugs – I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–1330.
   PubMed Web of Science ®Google Scholar
• Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs – II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331–1336.
   PubMed Web of Science ®Google Scholar
• Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17:14. DOI:10.3390/ijms17010014
   Web of Science ®Google Scholar
• Teschke R, Frenzel C, Wolff A, et al. Drug induced liver injury: accuracy of diagnosis in published reports. Ann Hepatol. 2014;13:248–255.
   PubMed Web of Science ®Google Scholar
• Björnsson ES. Hepatotoxicity by drugs: the most common implicated agents. Int J Mol Sci. 2016;17:224. DOI:10.3390/ijms17020224
   PubMed Web of Science ®Google Scholar
• Hayashi PH. Drug-induced liver injury network: causality assessment, criteria, and experience in the United States. Int J Mol Sci. 2016;17:201. DOI:10.3390/ijms17020201
   PubMed Web of Science ®Google Scholar
• Teschke R, Andrade R. Editorial. Drug-induced liver injury: expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment. Gastroenterology. 2015;148:1271–1273. DOI:10.1053/j.gastro.2015.04.027.
   PubMed Web of Science ®Google Scholar
• Ortega-Alonso A, Stephens C, Lucena MI, et al. Case characterization, clinical features and risk factors in drug-induced liver injury. Int J Mol Sci. 2016;17:714. DOI:10.3390/ijms17050714
   PubMed Web of Science ®Google Scholar
• Sarges P, Steinberg JM, Lewis JH. Drug-induced liver injury: highlights from a review of the 2015 literature. Drug Saf. 2016;39:561–575. DOI:10.1007/s4026401604278
   PubMed Web of Science ®Google Scholar
• Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451–455.
   PubMed Web of Science ®Google Scholar
• De Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: population based case–control study. Br J Clin Pharmacol. 2004;58:71–80.
   PubMed Web of Science ®Google Scholar
• Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–1425.
   PubMed Web of Science ®Google Scholar
• Melchart D, Hager S, Dai J, et al. Quality control and complication screening programme of Chinese medicinal drugs at the first German hospital of traditional chinese medicine – A retrospective analysis. Forsch Komplementmed. 2016;23(2):21–28.
   PubMedGoogle Scholar
• Douros A, Bronder E, Andersohn F, et al. Herb-induced liver injury in the Berlin case-control surveillance study. Int J Mol Sci. 2016;17:114. DOI:10.3390/ijms17010114.
   Web of Science ®Google Scholar
• Teschke R, Larrey D, Melchart D, et al. Traditional Chinese medicine (TCM) and herbal hepatotoxicity: RUCAM and the role of novel diagnostic biomarkers such as microRNAs. Medicines. 2016;3:18. DOI:10.3390/medicines3030018
   Google Scholar
• Frenzel C, Teschke R. Herbal hepatotoxicity: clinical characteristics and listing compilation. Int J Mol Sci. 2016;17:588. DOI:10.3390/ijms17050588.
   Web of Science ®Google Scholar
• Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Sem Liver Dis. 2009;29:337–347.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Affendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–530.
   PubMed Web of Science ®Google Scholar
• Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States: A population-based study. J Clin Gastroenterol. 2015;49:690–696.
   PubMed Web of Science ®Google Scholar
• Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58:388–396.
   PubMed Web of Science ®Google Scholar
• Yu K, Geng M, Zhang J, et al. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug induced liver injury. Drug Metab Dis. 2014;42:744–750.
   PubMed Web of Science ®Google Scholar
• Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47:2003–2009.
   PubMed Web of Science ®Google Scholar
• Lammert C, Bjornsson E, Niklasson A, et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse effects. Hepatology. 2010;51:615–620.
   PubMed Web of Science ®Google Scholar
• Franz CC, Egger S, Born C, et al. Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2012;68:179–188.
   PubMed Web of Science ®Google Scholar
• Lucena MI, Andrade RJ, Tognoni G, et al. Sanchez de la Cuesta F, and the Spanish group of therapeutic management in liver diseases drug use for non-hepatic associated conditions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2003;59:71–76.
   PubMed Web of Science ®Google Scholar
• Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis A practical guide. Aliment Pharmacol Ther. 2013;37:1132–1156.
   PubMed Web of Science ®Google Scholar
• Schlatterer-Häner C Dose adaptation of drugs in patients with liver disease. Thesis University Basel, 2009. Available from: http://edoc.unibas.ch/926/1/Dose_Adaptation_of_Drugs_in_Patients_with_Liver_Disease.pdf. cited 2016 Jun 20
   Google Scholar
• Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64:1147–1161.
   PubMed Web of Science ®Google Scholar
• Delcò F, Tchambaz L, Schlienger R, et al. Drug adjustment in patients with liver disease. Drug Saf. 2005;28:529–545.
   PubMed Web of Science ®Google Scholar
• Branch RA, Herbert CM, Read AE. Determinants of serum antipyrine half-lives in patients with liver disease. Gut. 1973;14:569–573.
   PubMed Web of Science ®Google Scholar
• Merrell MD, Cherrington NJ. Drug metabolism in nonalcoholic fatty liver disease. Drug Metab Rev. 2011;43:317–334.
   PubMed Web of Science ®Google Scholar
• Misra PS, Lefèvre A, Ishii H, et al. Increase of ethanol, meprobamate and pentobarbital after chronic ethanol administration in man and in rats. Am J Med. 1971;51:346–351.
   PubMed Web of Science ®Google Scholar
• Dyson JK, Hutchinson J, Harrison L, et al. Liver toxicity associated with sofobuvir, an NS5A inhibitor and ribavirin use. J Hepatol. 2016;64:234–238.
   PubMed Web of Science ®Google Scholar
• Gunaratnam NT, Benson J, Gandolfi AJ, et al. Suspected isoflurane hepatitis in an obese patient with a history of halothane hepatitis. Anesthesiology. 1995;83:1361–1364.
   PubMed Web of Science ®Google Scholar
• Tarantino G, Concha P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatology Res. 2007;37:410–415.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Sam J, Thuluvath PJ. Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminophen overdose in the United States. Hepatology. 2008;48:1336–1341.
   PubMed Web of Science ®Google Scholar
• Fromenty B. Drug-induced liver injury in obesity. J Hepatology. 2013;58:824–826.
   PubMed Web of Science ®Google Scholar
• Yoon E, Babar A, Choudhary M, et al. Acetaminophen-induced hepatotoxicity: a comprehensive update. J Clin Translat Hepatol. 2016;4:131–142.
   PubMed Web of Science ®Google Scholar
• Safari S, Motavaf M, Siamdoust SAS, et al. Hepatotoxicity of halogenated inhalation anesthetics. Iran Red Crescent Med J. 2014;16(9):e20153.
   PubMed Web of Science ®Google Scholar
• Gaude GS, Chaudhury A, Hattiholi J. Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients. J Family Med Prim Care. 2015;4:238–243. DOI:10.4103/2249-4863.154661.
   PubMedGoogle Scholar
• Lee SS, Lee CM, Kim TH, et al. Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016;20:800–805. DOI:10.5588/ijtld.15.0668.
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Merz M, Griffel L, et al. Liver safety assessment in special populations (hepatitis B, C, and oncology trials). Drug Saf. 2014;37(1):S57–S62.
   PubMed Web of Science ®Google Scholar
• Wang NT, Huang YS, Lin MH, et al. Chronic hepatitis B infection and risk of antituberculosis drug-induced liver injury: Systematic review and meta-analysis. J Chin Med Assoc. 2016;79:368–374. DOI:10.1016/j.
   PubMed Web of Science ®Google Scholar
• Gupta NK, Lewis JH. Review article: the use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther. 2008;28:1021–1041.
   PubMed Web of Science ®Google Scholar
• Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Sem Liver Dis. 2009;29:337–347.
   PubMed Web of Science ®Google Scholar
• Kim WS, Lee SS, Lee CM, et al. Hepatitis C and not hepatitis B virus is a risk factor for anti-tuberculous drug induced liver injury. BMC Infectious Dis. 2016;16:50.
   PubMed Web of Science ®Google Scholar
• Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther. 2007;26:1429–1435.
   PubMed Web of Science ®Google Scholar
• Davern TJ, Chalasani N, Fontana RJ, et al. for the drug-induced liver injury network (DILIN) acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141:1665–1672.
   PubMed Web of Science ®Google Scholar
• Chen EY, Baum K, Collins W, et al. Hepatitis E masquerading as drug–induced liver injury. Hepatology. 2012;56:2420–2423.
   PubMed Web of Science ®Google Scholar
• Begriche K, Massart J, Robin MA, et al. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol. 2011;54:773–794.
   PubMed Web of Science ®Google Scholar
• Aubert J, Begriche K, Knockaert L, et al. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: Mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol. 2011;35:630–637.
   PubMed Web of Science ®Google Scholar
• Rabinowich L, Shibolet O. Drug induced steatohepatitis: An uncommon culprit of a common disease. BioMed Res Intern. 2015;2015:1–14. Article ID 168905. DOI:10.1155/2015/168905
   Web of Science ®Google Scholar
• Teschke R, Stutz G, Strohmeyer G. Increased paracetamol-induced hepatotoxicity after chronic alcohol consumption. Biochem Biophys Res Commun. 1979;91:368–374.
   PubMed Web of Science ®Google Scholar
• Teschke R, Stutz G, Moreno F. Cholestasis following chronic ethanol consumption: enhancement after an acute dose of chlorpromazine. Biochem Biophys Res Commun. 1980;94:1013–1020.
   PubMed Web of Science ®Google Scholar
• Hasumura Y, Teschke R, Lieber CS. Increased carbon tetrachloride hepatotoxicity, and its mechanism, after chronic ethanol consumption. Gastroenterology. 1974;66:415–422.
   PubMed Web of Science ®Google Scholar
• O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol. 2010;105:14–32.
   PubMed Web of Science ®Google Scholar
• Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev. 1997;77:517–544.
   PubMed Web of Science ®Google Scholar
• Roberts H, Kruszon-Moran D, Ly KN, et al. Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988-2012. Hepatology. 2016;63:388–397. DOI:10.1002/hep.28109.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Wang CC, Welch S, et al. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology. 2012;56:422–433. DOI:10.1002/hep.24804.
   PubMed Web of Science ®Google Scholar
• Teschke R, Schulze J, Schwarzenboeck A, et al. Herbal hepatotoxicity: suspected cases assessed for alternative causes. Eur J Gastroenterol Hepatol. 2013;25:1093–1098. DOI:10.1097/MEG.0b013e3283603e89.
   PubMed Web of Science ®Google Scholar
• Teschke R, Schwarzenboeck A, Frenzel C, et al. The mystery of the Hawaii liver disease cluster in summer 2013: A pragmatic and clinical approach to solve the problem. Ann Hepatol. 2016;15:91–119. cited 2016 Jul 8. Available from http://www.annalsofhepatology.com.mx/revista/numeros/2016/HP161-12-Mystery%20(web)%20(FF_041215V)_PROTEGIDO%20(1).pdf
   PubMed Web of Science ®Google Scholar
• Teschke R, Eickhoff A. The honolulu liver disease cluster at the medical center: its mysteries and challenges. Int J Mol Sci. 2016;17(4):476. DOI:10.3390/ijms17040476
   PubMed Web of Science ®Google Scholar
• Heidemann LA, Navarro VJ, Ahmad J, et al. Severe acute hepatocellular injury attributed to oxyELITE pro: A case series. Dig Dis Sci. 2016;61:2741–2747. DOI:10.1007/s10620-016-4181-7.
   PubMed Web of Science ®Google Scholar
• Teschke R, Frenzel C. Drug induced liver injury: do we still need a routine liver biopsy for diagnosis today? Ann Hepatol. 2014;13:121–126.
   Web of Science ®Google Scholar
• Kleiner DE, Chalasani NP, Lee WM, et al. for the Drug-Induced Liver Injury Network (DILIN) hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59:661–670.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines of chronic hepatitis B. Hepatology. 2016;63:261–283.
   PubMed Web of Science ®Google Scholar
• Merz M, Lee KR, Kullak-Ublick GA, et al. Methodology to assess clinical liver safety data. Drug Saf. 2014;37(1):S33–S45.
   PubMed Web of Science ®Google Scholar
• Chang ML, Liaw YF. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J Hepatology. 2014;61:1407–1412.
   PubMed Web of Science ®Google Scholar
• Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–521.
   PubMed Web of Science ®Google Scholar
• EASL. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.
   PubMed Web of Science ®Google Scholar
• Teschke R, Danan G. Diagnosis and management of drug-induced liver injury (DILI) in patients with pre-existing liver disease. Drug Saf. 2016;39:729–744. DOI:10.1007/s40264-016-0423-z
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Nelson KE, Purcell RH. Review article: hepatitis E. N Engl J Med. 2012;367:1237–1244.
   PubMed Web of Science ®Google Scholar
• Kokki I, Smith D, Simmonds P, et al. Hepatitis E is the leading cause of acute viral hepatitis in Lothian, Scotland. New Microbe New Infect. 2016;10:6–12.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Hepatitis E information. Hepatitis E FAQs for health professionals. cited 2015 Dec 18 . Available from: http://www.cdc.gov/hepatitis/hev/hevfaq.htm. cited 2016 Jul 8.
   Google Scholar
• Teschke R, Schulze J, Eickhoff A, et al. Mysterious Hawaii liver disease case – Naproxen overdose as cause rather than oxyELITE pro? J Liver Clin Res. 2015;2. cited 2016 Jul 8. Available from http://www.jscimedcentral.com/Liver/liver-2-1013.pdf
   Google Scholar
• Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol. 2008;66:758–766.
   PubMed Web of Science ®Google Scholar
• Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicentre, prospective study. Hepatology. 2005;42:1364–1372.
   PubMed Web of Science ®Google Scholar
• Myers RP, Shaheen AAM, Li B, et al. Impact of liver disease, alcohol abuse, and unintentional ingestions on the outcomes of acetaminophen overdose. Clin Gastroenterol Hepatol. 2008;6:918–925.
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Tulkens PM. Hepatic safety of antibiotics in primary care. Antimicrob Chemother. 2011;66:1431–1446.
   Web of Science ®Google Scholar
• Kramer JR, Giordano TP, Souchek J, et al. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol. 2005;42:309–314.
   PubMed Web of Science ®Google Scholar
• Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clin Infect Dis. 2004;38(Suppl 2):S104–S108.
   PubMed Web of Science ®Google Scholar
• Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug–induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157:1871–1876.
   PubMed Web of Science ®Google Scholar
• Saukkonen JJ, Cohn DL, Jasmer RM, et al. on behalf of the ATS hepatotoxicity of antituberculosis therapy subcommittee an official ATS statement: hepatotoxicity of antituberculous therapy. Am J Crit Car Med. 2006;174:935–952.
   PubMed Web of Science ®Google Scholar
• Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology. 2000;31:201–206.
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Lustbader ED, Sharrar RG, et al. Isoniazid prophylaxis in hepatitis B carriers. Am Rev Respir Dis. 1986;134:666–668.
   PubMed Web of Science ®Google Scholar
• Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol. 2002;97:1198–1203.
   PubMed Web of Science ®Google Scholar
• Wu JC, Lee SD, Yeh PF, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology. 1990;98:502–504.
   PubMed Web of Science ®Google Scholar
• Amarapurkar DN, Prabhudesai PP, Kalro RH, et al. Antituberculosis drug-induced hepatitis and HBsAg carriers. Tuberc Lung Dis. 1993;74:215–216.
   PubMedGoogle Scholar
• Hwang SJ, Wu JC, Lee CN, et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol. 1997;12:87–91.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1278–1292.
   Web of Science ®Google Scholar
• Russo MW, Watkins PB. Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology. 2004;126:1477–1480.
   PubMed Web of Science ®Google Scholar
• Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005;41:690–695.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56:374–380.
   PubMed Web of Science ®Google Scholar
• Teschke R, Zhang L, Melzer L, et al. Green tea extract and the risk of drug-induced liver injury. Expert Opin Drug Metab Toxicol. 2014;10:1663–1676. DOI:10.1517/17425255.2014.971011.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 889 patients with drug- induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148:1340–1352. DOI:10.1053/j.gastro.2015.03.00696.
   PubMed Web of Science ®Google Scholar
• Teschke R, Andrade RJ. Editorial of special issue “drug, herb, and dietary supplement hepatotoxicity. Int J Mol Sci. 2016;17:711.
   Web of Science ®Google Scholar